Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Yum! Brands (YUM) upgraded to Outperform on valuation at Evercore ISI with analyst Matt MCGinley saying he changed his view due to the recent pullback in shares and said there is solid visibility into multi-year earnings growth from G&A reductions and share buybacks. 2. AbbVie (ABBV) upgraded to Conviction Buy from Buy at Goldman with analyst Jami Rubin saying it is one of the most compelling values across healthcare coverage, let alone U.S. pharma. 3. Fairmount Santrol (FMSA) upgraded to Buy from Hold at Jefferies with analyst Brad Handler saying the 41% pullback in shares over the past two weeks does not reflect industry fundamentals. The analyst remains comfortable with medium term frac sand industry demand/supply fundamentals. He lowered his price target for the shares to $10 from $12. 4. Fly Leasing (FLY) upgraded to Buy from Neutral at Compass Point. 5. Camden Property (CPT) upgraded to Buy from Neutral at Goldman with analyst Andrew Rosivach citing lower supply and "sustained strong demand," particularly in Houston. The analyst raised his price target for the shares to $94 from $84. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Sees FY24: Skyrizi revenue $10.7B; Rinvoq revenue $5.6B; Imbruvica revenue $3.1B; Elahere revenue $450M. Sees FY24 adjusted gross margin 84%. Expects FX to have 0.9% impact on FY sales.

Says "successfully navigating" Humira loss of exclusivity. Says executing well across all aspects of the business. Says multiple growth drivers to support long term outlook. Says continues to advance R&D pipeline. Says well positioned to deliver high single digit revenue CAGR through end of decade. Comments taken from Q1 earnings conference call.

Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - U... To see the rest of the story go to thefly.com. See Story Here

Global net revenues from the immunology portfolio were $5.371B, a decrease of 3.9 percent on a reported basis, or 3.1 percent on an operational basis, due to Humira biosimilar competition. Global Humira net revenues of $2.270 billion decreased 35.9 percent on a reported basis, or 35.2 percent on an operational basis. U.S. Humira net revenues were $1.771 billion, a decrease of 39.9 percent. Internationally, Humira net revenues were $499 million, a decrease of 15.8 percent on a reported basis, or 11.6 percent on an operational basis. Global Skyrizi net revenues were $2.008 billion, an increase of 47.6 percent on a reported basis, or 48.0 percent on an operational basis. Global Rinvoq net revenues were $1.093 billion, an increase of 59.3 percent on a reported basis, or 61.9 percent on an operational basis.

FY24 consensus $11.10.

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.